Stalevo in Early Wearing-Off Patients

Multicentre, Randomised, Double-Blind Study to Compare Stalevo to Levodopa/Carbidopa in Patients With Parkinson's Disease Experiencing Symptoms of Early Wearing-Off

The purpose of this study is to demonstrate in patients with Parkinson's disease that, when compared to levodopa/carbidopa, Stalevo will delay the time from initiation of study drug to the time an increase in antiparkinsonian medication is required due to inadequately controlled parkinsonian symptoms.

Inclusion Criteria:

• Idiopathic Parkinson's disease
• Treatment with 3 equal daily doses of levodopa/carbidopa up to 450 mg/day
• Unchanged antiparkinsonian medication for 6 weeks prior to baseline

Exclusion Criteria:

• Secondary or atypical parkinsonism
• Patients with daily unpredictable OFF periods or painful dyskinesia